NCT07802704: A Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) [EMBOLD Prostate-302]
- State
- Under way
- Phase
- Phase 3
- People
- 684 planned
- Started
- 1 Sep 2026
- Primary completion
- 5 Dec 2029
- Arms
- Risvutatug rezetecan (Ris-Rez)
- Results
- None posted
- 1 Sep 2026: Trial started
- 3 Sep 2026: Trial registered